23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
10 janv. 2022 08h00 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health...
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
06 janv. 2022 09h00 HE
|
23andMe Holding Co.
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey...
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
28 déc. 2021 16h05 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed...
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
30 nov. 2021 09h15 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R....
23andMe Announces Redemption of All Outstanding Warrants
22 nov. 2021 16h15 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its...
23andMe Reports FY2022 Second Quarter Financial Results
10 nov. 2021 16h05 HE
|
23andMe Holding Co.
Second quarter revenue of $55 millionRecent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE,...
23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders
03 nov. 2021 16h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe Announces the Closing of its Acquisition of Lemonaid Health
01 nov. 2021 16h05 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its...
23andMe Agrees to Acquire Lemonaid Health
22 oct. 2021 06h55 HE
|
23andMe, Inc.
Acquisition provides telemedicine platform for 23andMe to advance its vision of individualized primary care that empowers consumers to live healthier lives 23andMe to host investor webcast today at...
23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021
20 oct. 2021 18h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...